142 related articles for article (PubMed ID: 38194844)
1. To assess the quantitative features of focal liver lesions in gadoxetic acid enhanced MRI and to determine whether these features can accurately differentiate benign form malignant lesions.
Rybczynska DN; Markiet KE; Pienkowska JM; Szurowska E; Frydrychowski A
Eur J Radiol; 2024 Feb; 171():111288. PubMed ID: 38194844
[TBL] [Abstract][Full Text] [Related]
2. Value of Texture Analysis on Gadoxetic Acid-Enhanced MRI for Differentiating Hepatocellular Adenoma From Focal Nodular Hyperplasia.
Cannella R; Rangaswamy B; Minervini MI; Borhani AA; Tsung A; Furlan A
AJR Am J Roentgenol; 2019 Mar; 212(3):538-546. PubMed ID: 30557050
[TBL] [Abstract][Full Text] [Related]
3. [Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyperplasia and hepatocellular adenoma].
Portilha MA; Pedro MT; Ruivo C; Semedo LC; Marques C; Alves FC
Acta Med Port; 2011 Dec; 24 Suppl 2():531-8. PubMed ID: 22849944
[TBL] [Abstract][Full Text] [Related]
4. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
Vanhooymissen IJSML; Thomeer MG; Braun LMM; Gest B; van Koeverden S; Willemssen FE; Hunink M; De Man RA; Ijzermans JN; Dwarkasing RS
J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
[TBL] [Abstract][Full Text] [Related]
5. Efficacy comparison of multi-phase CT and hepatotropic contrast-enhanced MRI in the differential diagnosis of focal nodular hyperplasia: a prospective cohort study.
Nowicki TK; Markiet K; Izycka-Swieszewska E; Dziadziuszko K; Studniarek M; Szurowska E
BMC Gastroenterol; 2018 Jan; 18(1):10. PubMed ID: 29334905
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of morphological enhancement patterns in the hepatobiliary phase of gadoxetic acid-enhanced MRI to distinguish focal nodular hyperplasia from hepatocellular adenoma.
Bilreiro C; Soler JC; Ayuso JR; Caseiro-Alves F; Ayuso C
Radiol Med; 2021 Nov; 126(11):1379-1387. PubMed ID: 34287759
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.
Roux M; Pigneur F; Calderaro J; Baranes L; Chiaradia M; Tselikas L; Decaens T; Costentin C; Laurent A; Azoulay D; Mallat A; Zafrani ES; Rahmouni A; Luciani A
J Magn Reson Imaging; 2015 Nov; 42(5):1249-58. PubMed ID: 25851028
[TBL] [Abstract][Full Text] [Related]
8. Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful?
Roux M; Pigneur F; Baranes L; Calderaro J; Chiaradia M; Decaens T; Kastahian S; Charles-Nelson A; Tselikas L; Costentin C; Laurent A; Azoulay D; Mallat A; Rahmouni A; Luciani A
Abdom Radiol (NY); 2018 Jul; 43(7):1670-1681. PubMed ID: 29110059
[TBL] [Abstract][Full Text] [Related]
9. Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.
Reizine E; Amaddeo G; Pigneur F; Baranes L; Legou F; Mulé S; Zegai B; Roche V; Laurent A; Rahmouni A; Calderaro J; Luciani A
Eur Radiol; 2018 Oct; 28(10):4243-4253. PubMed ID: 29721686
[TBL] [Abstract][Full Text] [Related]
10. 3D variable flip angle T1 mapping for differentiating benign and malignant liver lesions at 3T: comparison with diffusion weighted imaging.
Wang F; Yang Q; Zhang Y; Liu J; Liu M; Zhu J
BMC Med Imaging; 2022 Aug; 22(1):146. PubMed ID: 35982406
[TBL] [Abstract][Full Text] [Related]
11. Utility of diffusion-weighted MRI in distinguishing benign and malignant hepatic lesions.
Miller FH; Hammond N; Siddiqi AJ; Shroff S; Khatri G; Wang Y; Merrick LB; Nikolaidis P
J Magn Reson Imaging; 2010 Jul; 32(1):138-47. PubMed ID: 20578020
[TBL] [Abstract][Full Text] [Related]
12. HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI.
Auer TA; Walter-Rittel T; Geisel D; Schöning W; Schmelzle M; Müller T; Sinn B; Denecke T; Hamm B; Fehrenbach U
BMC Med Imaging; 2021 Feb; 21(1):28. PubMed ID: 33588783
[TBL] [Abstract][Full Text] [Related]
13. Utility of volumetric contrast-enhanced and diffusion-weighted MRI in differentiating between common primary hypervascular liver tumors.
Zarghampour M; Fouladi DF; Pandey A; Ghasabeh MA; Pandey P; Varzaneh FN; Khoshpouri P; Shao N; Pan L; Grimm R; Kamel IR
J Magn Reson Imaging; 2018 Oct; 48(4):1080-1090. PubMed ID: 29630756
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of diffusion weighted MRI and ADC in differential diagnosis of cavernous hemangioma of the liver.
Tokgoz O; Unlu E; Unal I; Serifoglu I; Oz I; Aktas E; Caglar E
Afr Health Sci; 2016 Mar; 16(1):227-33. PubMed ID: 27358636
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory hepatocellular adenomas can mimic focal nodular hyperplasia on gadoxetic acid-enhanced MRI.
Agarwal S; Fuentes-Orrego JM; Arnason T; Misdraji J; Jhaveri KS; Harisinghani M; Hahn PF
AJR Am J Roentgenol; 2014 Oct; 203(4):W408-14. PubMed ID: 25055198
[TBL] [Abstract][Full Text] [Related]
16. Hepatic Adenoma Subtypes on Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI: Systematic Review and Meta-Analysis.
Kim TH; Woo S; Ebrahimzadeh S; McInnes MDF; Gerst SR; Do RK
AJR Am J Roentgenol; 2023 Jan; 220(1):28-38. PubMed ID: 35920706
[No Abstract] [Full Text] [Related]
17. Comparison of magnetic resonance elastography and diffusion-weighted imaging for differentiating benign and malignant liver lesions.
Hennedige TP; Hallinan JT; Leung FP; Teo LL; Iyer S; Wang G; Chang S; Madhavan KK; Wee A; Venkatesh SK
Eur Radiol; 2016 Feb; 26(2):398-406. PubMed ID: 26032879
[TBL] [Abstract][Full Text] [Related]
18. Can diffusion-weighted imaging distinguish between benign and malignant pediatric liver tumors?
Caro-Domínguez P; Gupta AA; Chavhan GB
Pediatr Radiol; 2018 Jan; 48(1):85-93. PubMed ID: 28921384
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of gadoxetic acid-enhanced MRI for the differential diagnosis of focal liver lesions: Comparison between estimated intralesional gadoxetic acid retention by T1 mapping and conventional processing methods.
Morisaka H; Seno D; Sakurai Y; Sano K; Akamine Y; Ichikawa T; Okada Y
Eur J Radiol; 2021 May; 138():109620. PubMed ID: 33713905
[TBL] [Abstract][Full Text] [Related]
20. Gadoxetic acid enhanced MRI for differentiation of FNH and HCA: a single centre experience.
Grieser C; Steffen IG; Kramme IB; Bläker H; Kilic E; Perez Fernandez CM; Seehofer D; Schott E; Hamm B; Denecke T
Eur Radiol; 2014 Jun; 24(6):1339-48. PubMed ID: 24658870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
